Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Cited by (1,002)

Items 101–200 of 1,002

1. High-throughput and single-cell T cell receptor sequencing technologies
   Joy A. Pai, Ansuman T. Satpathy · 2021 · Nature Methods
2. Genetic and non-genetic clonal diversity in cancer evolution
   James R. Black, Nicholas McGranahan · 2021 · Nature reviews. Cancer
3. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
   Zijun Yidan Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H. Young · 2017 · Frontiers in Immunology
4. Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment
   Chenxi Ma, Chengzhe Yang, Ai Fen Peng, Tianyong Sun, Xiaoli Ji, Jun Mi, Wei Li, Song Shen, Qiang Feng · 2023 · Molecular Cancer
5. Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
   Jenny Lee, Elena Shklovskaya, Su Yin Lim, Matteo Salvatore Carlino, Alexander Maxwell Menzies, Ashleigh Stewart, Bernadette Pedersen, Malama Irvine, Sara Alavi, Jean Yee Hwa Yang et al. · 2020 · Nature Communications
6. Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-α
   Lijian Wu, Yiteng Jin, Xi Zhao, Kaiyang Tang, Yaoning Zhao, Linjie Tong, Xuerong Yu, Ke Xiong, Ce Luo, Jiajun Zhu et al. · 2023 · Cell Metabolism
7. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
   Kelly Garneski Paulson, Valentin Voillet, Megan S. McAfee, Daniel S. Hunter, Felecia D. Wagener, Maurizio Perdicchio, William J. Valente, Samson Koelle, Candice D. Church, Natalie A. Vandeven et al. · 2018 · Nature Communications
8. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
   Pauken, Kristen E., Dougan, Michael, Rose, Noel R., Lichtman, Andrew H., Sharpe, Arlene H. · 2019 · Trends in Immunology
9. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response
   Zhen Zhang, Zixian Wang, Yan‐Xing Chen, Hao‐Xiang Wu, Ling Yin, Qi Zhao, Hui Luo, Zhao-Lei Zeng, Miao‐Zhen Qiu, Rui‐Hua Xu · 2022 · Genome Medicine
10. CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
    Kagamu, Hiroshi, Kitano, Shigehisa, Yamaguchi, Ou, Yoshimura, Kenichi, Horimoto, Katsuhisa, Kitazawa, Masashi, Fukui, Kazuhiko, Shiono, Ayako, Mouri, Atsuhito, Nishihara, Fuyumi et al. · 2020 · Cancer Immunology Research
11. Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
    Vredevoogd, David W., Kuilman, Thomas, Ligtenberg, Maarten A., Boshuizen, Julia, Stecker, Kelly E., de Bruijn, Beaunelle, Krijgsman, Oscar, Huang, Xinyao, Kenski, Juliana C.N., Lacroix, Ruben et al. · 2019 · Cell
12. Promises and challenges of adoptive T-cell therapies for solid tumours
    Matteo Morotti, Ashwag Albukhari, Abdulkhaliq Alsaadi, Mara Artibani, James D. Brenton, Stuart M. Curbishley, Tao Dong, Michael Loran Dustin, Zhiyuan Hu, Nicholas McGranahan et al. · 2021 · British Journal of Cancer
13. Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy
    Gi‐Hoon Nam, Yoonjeong Choi, Gi Beom Kim, Seohyun Kim, Seong A Kim, In‐San Kim · 2020 · Advanced Materials
14. TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
    Jiefei Han, Jianchun Duan, Hua Bai, Yuqi Wang, Rui Wan, Xin Wang, Si Chen, Yanhua Tian, Di Wang, Kailun Fei et al. · 2019 · Cancer Immunology Research
15. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
    Daniele Biasci, Martin Smoragiewicz, Claire M. Connell, Zhikai Wang, Ya Gao, James E. D. Thaventhiran, Bristi Basu, Łukasz Magiera, Timothy Isaac Johnson, Lisa Bax et al. · 2020 · Proceedings of the National Academy of Sciences
16. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
    Diego Chowell, Seong‐Keun Yoo, Cristina Valero, Alessandro Pastore, Chirag Krishna, Mark Lee, Douglas Robert Hoen, Hongyu Shi, Daniel W. Kelly, Neal Patel et al. · 2021 · Nature Biotechnology
17. A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
    Hagma H. Workel, Joyce M. Lubbers, Roland R. Arnold, Thalina M. Prins, Pieter van der Vlies, Kim de Lange, Tjalling Bosse, Inge C. van Gool, Florine A. Eggink, Maartje C.A. Wouters et al. · 2019 · Cancer Immunology Research
18. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
    Lewis Au, Emine Hatipoglu, Marc Robert de Massy, Kevin Litchfield, Gordon Beattie, Andrew Rowan, Désirée Schnidrig, R. Houston Thompson, Fiona Byrne, Stuart D. Horswell et al. · 2021 · Cancer Cell
19. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer
    Hammerl, Dora, Martens, John W. M., Timmermans, Mieke, Smid, Marcel, Trapman-Jansen, Anita M., Foekens, Renée, Isaeva, Olga I., Voorwerk, Leonie, Balcioglu, Hayri E., Wijers, Rebecca et al. · 2021 · Nature Communications
20. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer
    Song Li, Wenbin Yu, Fei Xie, Haitao Luo, Zhimin Liu, Weiwei Lv, Duan‐Bo Shi, Dexin Yu, Peng Gao, Cheng Chen et al. · 2023 · Nature Communications
21. Host tissue determinants of tumour immunity
    Hélène Salmon, Romain Remark, Sacha Gnjatic, Miriam Mérad · 2019 · Nature reviews. Cancer
22. Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade
    Eduardo Bonavita, Christian P. Bromley, Gustav Jonsson, Victoria S. Pelly, Sudhakar Sahoo, Katherine Walwyn-Brown, Sofia Mensurado, Agrin Moeini, Eimear Flanagan, Charlotte R. Bell et al. · 2020 · Immunity
23. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
    Hwang, Sohyun, Kwon, Ah-Young, Jeong, Ju-Yeon, Kim, Sewha, Kang, Haeyoun, Park, Joonsuk, Kim, Joo-Hang, Han, Ok Jin, Lim, Sun Min, An, Hee Jung · 2020 · Scientific Reports
24. Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation
    Yu, Man, Peng, Zhengxin, Qin, Min, Liu, Yang, Wang, Jingning, Zhang, Cai, Lin, Jiaming, Dong, Tianqi, Wang, Lulu, Li, Shasha et al. · 2021 · Molecular Cell
25. Assessing the interactions between radiotherapy and antitumour immunity
    Grassberger, Clemens, Ellsworth, Susannah G., Wilks, Moses Q., Keane, Florence K., Loeffler, Jay S. · 2019 · Nature Reviews Clinical Oncology
26. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
    Christine D. Palmer, Amy Rappaport, Matthew J. Davis, Meghan G. Hart, Ciaran D. Scallan, Sue‐Jean Hong, Leonid Gitlin, Lauren D. Kraemer, Sonia Kounlavouth, Aaron Yang et al. · 2022 · Nature Medicine
27. Mechanisms of immune activation and regulation: lessons from melanoma
    Shelly Kalaora, Adi Nagler, Jennifer Ann Wargo, Yardena Samuels · 2022 · Nature reviews. Cancer
28. Cancer immunotherapy: broadening the scope of targetable tumours
    Jitske van den Bulk, Els M.E. Verdegaal, Noel F.C.C. de Miranda · 2018 · Open Biology
29. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions
    Albrecht Stenzinger, Jeffrey D. Allen, J. Maas, Mark D. Stewart, Diana M. Merino, Madison M. Wempe, Manfred Dietel · 2019 · Genes Chromosomes and Cancer
30. Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
    Jean-David Fumet, Caroline Truntzer, Mark M. Yarchoan, François Ghiringhelli · 2020 · European Journal of Cancer
31. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
    Dubrot, Juan, Du, Peter P., Lane-Reticker, Sarah Kate, Kessler, Emily A., Muscato, Audrey J., Mehta, Arnav, Freeman, Samuel S., Allen, Peter M., Olander, Kira E., Ockerman, Kyle M. et al. · 2022 · Nature Immunology
32. FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
    Wang, Ye, Tong, Zhuang, Zhang, Wenhua, Zhang, Weizhen, Buzdin, Anton, Mu, Xiaofeng, Yan, Qing, Zhao, Xiaowen, Chang, Hui-Hua, Duhon, Mark et al. · 2021 · Frontiers in Oncology
33. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
    Guangchun Han, Guoliang Yang, Dapeng Hao, Yang Lü, Kyaw Zin Thein, Benjamin Scott S Simpson, Jianfeng Chen, Ryan Sun, Omar Alhalabi, Ruiping Wang et al. · 2021 · Nature Communications
34. An RNA toolbox for cancer immunotherapy
    Pastor, Fernando, Berraondo, Pedro, Etxeberria, Iñaki, Frederick, Josh, Sahin, Ugur, Gilboa, Eli, Melero, Ignacio · 2018 · Nature Reviews Drug Discovery
35. Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
    Venus Sosa Iglesias, Lorena Giuranno, Ludwig Jerome Dubois, Jan Theys, Marc Vooijs · 2018 · Frontiers in Oncology
36. Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1
    Joo Sang Lee, Eytan Ruppin · 2019 · JAMA Oncology
37. m6A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer
    Wei Chong, Liang Shang, Jin Liu, Zhen Fang, Fengying Du, Hao Wu, Liu Yang, Zhe Wang, Yang Chen, Shengtao Jia et al. · 2020 · Theranostics
38. Metabolomic adaptations and correlates of survival to immune checkpoint blockade
    Li, Haoxin, Bullock, Kevin, Gurjao, Carino, Braun, David, Shukla, Sachet A., Bossé, Dominick, Lalani, Aly-Khan A., Gopal, Shuba, Jin, Chelsea, Horak, Christine et al. · 2019 · Nature Communications
39. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
    Samstein, Robert M., Krishna, Chirag, Ma, Xiaoxiao, Pei, Xin, Lee, Ken-Wing, Makarov, Vladimir, Kuo, Fengshen, Chung, Jonathan, Srivastava, Raghvendra M., Purohit, Tanaya A. et al. · 2020 · Nature Cancer
40. PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
    Gabrielle Planes-Laine, Philippe Rochigneux, François Bertucci, Anne-Sophie Chrétien, Patrice Viens, Renaud Sabatier, Anthony Gonçalvès · 2019 · Cancers
41. Network-based machine learning approach to predict immunotherapy response in cancer patients
    Kong, JungHo, Ha, Doyeon, Lee, Juhun, Kim, Inhae, Park, Minhyuk, Im, Sin-Hyeog, Shin, Kunyoo, Kim, Sanguk · 2022 · Nature Communications
42. TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts
    Grauel, Angelo L., Nguyen, Beverly, Ruddy, David, Laszewski, Tyler, Schwartz, Stephanie, Chang, Jonathan, Chen, Julie, Piquet, Michelle, Pelletier, Marc, Yan, Zheng et al. · 2020 · Nature Communications
43. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
    Kristina Buder‐Bakhaya, Jessica C. Hassel · 2018 · Frontiers in Immunology
44. Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities
    Roy Rabbie, Peter M. Ferguson, Christian Molina‐Aguilar, David J. Adams, Carla Daniela Robles‐Espinoza · 2018 · The Journal of Pathology
45. Methionine deficiency facilitates antitumour immunity by altering m 6 A methylation of immune checkpoint transcripts
    Ting Li, Yue‐Tao Tan, Yan‐Xing Chen, Xiaojun Zheng, Wen Wang, Kun Lun Liao, Hai‐Yu Mo, Junzhong Lin, Wei Yang, Hai‐long Piao et al. · 2022 · Gut
46. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
    Rachael M. Zemek, Emma de Jong, Wee Loong Chin, Iona S. Schuster, Vanessa S. Fear, Thomas H. Casey, Cath Forbes, Sarah Dart, Connull Leslie, Ayham Zaitouny et al. · 2019 · Science Translational Medicine
47. Current Perspectives in Cancer Immunotherapy
    Theodoulakis Christofi, Stavroula Baritaki, Luca Falzone, Massimo Libra, Apostolos Zaravinos · 2019 · Cancers
48. Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer
    Yuqing Chen, Dongfang Wang, Yingjie Li, Qi Lu, Wen Si, Yufei Bo, Xueyan Chen, Zhaochen Ye, Hongtao Fan, Baolin Liu et al. · 2024 · Cancer Cell
49. A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response
    Donghai Xiong, Yian Wang, Ming You · 2020 · Nature Communications
50. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
    Wenfeng Fang, Yuxiang Ma, Jiani C. Yin, Shaodong Hong, Huaqiang Zhou, Ao Wang, Fufeng Wang, Hua Bao, Xue Wu, Yunpeng Yang et al. · 2019 · Clinical Cancer Research
51. Intratumoral CXCL13 + CD8 + T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma
    Siyuan Dai, Han Zeng, Zhaopei Liu, Kaifeng Jin, Wenbin Jiang, Zewei Wang, Zhiyuan Lin, Ying Xiong, Jiajun Wang, Yuan Chang et al. · 2021 · Journal for ImmunoTherapy of Cancer
52. Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses
    Felix Bayerl, Philippa Meiser, Sainitin Donakonda, Anna Hirschberger, Sebastian B. Lacher, Anna‐Marie Pedde, Chris D. Hermann, Anais Elewaut, Moritz A. Knolle, Lukas Ramsauer et al. · 2023 · Immunity
53. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target
    Xiaoqing Wang, Collin J. Tokheim, Shengqing Stan Gu, Binbin Wang, Qin Tang, Yihao Li, Nicole C. Traugh, Zexian Zeng, Yi Zhang, Ziyi Li et al. · 2021 · Cell
54. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes
    Joshua J. Meeks, Hikmat A Al‐Ahmadie, Bishoy M. Faltas, John Arthur Taylor, Thomas W. Flaig, David J. DeGraff, Emil Christensen, Benjamin Leeland Woolbright, David James McConkey, Lars Dyrskjøt · 2020 · Nature Reviews Urology
55. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors
    Szonja Kovacs, János Tibor Fekete, Balázs Győrffy · 2023 · Acta Pharmacologica Sinica
56. The Immune Subtypes and Landscape of Squamous Cell Carcinoma
    Bailiang Li, Yi Cui, Dhanya K. Nambiar, John B. Sunwoo, Ruijiang Li · 2019 · Clinical Cancer Research
57. LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy
    Gaopeng Li, Ilona Kryczek, Jutaek Nam, Xiong Li, Shasha Li, Jing Li, Shuang Wei, Sara Grove, Linda Vatan, Jiajia Zhou et al. · 2021 · Nature Cell Biology
58. Resistance mechanisms to immune checkpoint inhibitors: updated insights
    Besan H. Al-Saafeen, Bassam R. Ali, Eyad Elkord · 2025 · Molecular Cancer
59. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival
    Sara Valpione, Piyushkumar A. Mundra, Elena Galvani, Luca Giovanni Campana, Paul C. Lorigan, Francesco De Rosa, Avinash Gupta, John Weightman, Sarah Catherine Mills, Nathalie S. Dhomen et al. · 2021 · Nature Communications
60. Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
    Arsela Prelaj, Rebecca Yin Tay, Roberto Ferrara, Nathalie Chaput, Benjamin Besse, Raffaele Califano · 2018 · European Journal of Cancer
61. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
    Jing Li, Weichao Wang, Yajia Zhang, Marcin P. Cieslik, Jipeng Guo, Mengyao Tan, Michael D. Green, Weimin Wang, Heng Lin, Wei Li et al. · 2020 · Journal of Clinical Investigation
62. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation
    Jaikumar Duraiswamy, Riccardo Turrini, Aspram Minasyan, David Barras, Isaac Crespo, Alizée J Grimm, Julia Casado, Raphaël Genolet, Fabrizio Benedetti, Alexandre M. Wicky et al. · 2021 · Cancer Cell
63. Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy
    Hanbing Wang, Baorui Liu, Jia Wei · 2021 · Cancer Letters
64. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
    Rajasekharan Somasundaram, Thomas Connelly, Robin Choi, Hyeree Choi, Anastasia Samarkina, Ling Li, Elizabeth Gregorio, Yeqing Chen, Rohit Thakur, Mohamed Abdel‐Mohsen et al. · 2021 · Nature Communications
65. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion
    Isak W. Tengesdal, D. R. Menon, D. G. Osborne, C. Neff, Nicholas E. Powers, F. Gamboni, A. Mauro, A. D'Alessandro, D. Stefanoni, M. Henen et al. · 2021 · Proceedings of the National Academy of Sciences of the United States of America
66. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity
    Anthony Richard Cillo, Carly Cardello, Feng Shan, Lilit Karapetyan, Sheryl R. Kunning, Cindy Sander, Elizabeth A. Rush, Arivarasan D. Karunamurthy, Ryan Campbell Massa, Anjali Rohatgi et al. · 2024 · Cell
67. Melanoma: What do all the mutations mean?
    Elizabeth J. Davis, Douglas Buckner Johnson, Jeffrey Alan Sosman, Sunandana Chandra · 2018 · Cancer
68. Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
    Hao Chen, Wei Chong, Qian Wu, Yueliang Yao, Min Mao, Xin Wang · 2019 · Frontiers in Immunology
69. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response
    Jingjing He, Xinxin Xiong, Han Yang, Dandan Li, Xuefei Liu, Shuo Li, Shuangye Liao, Siyu Chen, Xizhi Wen, Kuai Yu et al. · 2022 · Cell Research
70. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer
    Jashodeep Datta, Xizi Dai, Anna Bianchi, Iago De Castro Silva, Siddharth Mehra, Vanessa T. Garrido, Purushottam Lamichhane, Samara P. Singh, Zhiqun Zhou, Austin R. Dosch et al. · 2021 · Gastroenterology
71. Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion
    Junli Lu, Yiming Luo, Dean Rao, Tiantian Wang, Zhen Lei, Xiaoping Chen, Bixiang Zhang, Yiwei Li, Bi‐Feng Liu, Limin Xia et al. · 2024 · Experimental Hematology and Oncology
72. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
    Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher M. Attwood, Sebastiano Battaglia, Saby George, Gurkamal S. Chatta, Igor J. Puzanov et al. · 2021 · Nature Communications
73. CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer
    Lin, Anqi, Qi, Chang, Wei, Ting, Li, Mengyao, Cheng, Quan, Liu, Zaoqu, Luo, Peng, Zhang, Jian · 2022 · Briefings in Bioinformatics
74. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
    Amy L. Shergold, Rhona Millar, Robert J. B. Nibbs · 2019 · Pharmacological Research
75. Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses
    Jay K. Mandula, Shiun Chang, Eslam T. Mohamed, Rachel Jimenez, Rosa A. Sierra-Mondragon, Darwin Chang, Alyssa Obermayer, Carlos Moran Segura, Satyajit Das, Julio Angel Vázquez-Martínez et al. · 2022 · Cancer Cell
76. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop
    Yichao Hua, Gerlanda Vella, Florian Rambow, Elizabeth Allen, Asier Antoranz, Marie Duhamel, Akira Takeda, Sirpa Jalkanen, Steffie Junius, Ann Smeets et al. · 2022 · Cancer Cell
77. PIRD: pan immune repertoire database
    Zhang, Wei, Wang, Longlong, Liu, Ke, Wei, Xiaofeng, Yang, Kai, Du, Wensi, Wang, Shiyu, Guo, Nannan, Ma, Chuanchuan, Luo, Lihua et al. · 2020 · Bioinformatics
78. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition
    Girish S. Naik, Sushrut S. Waikar, Alistair E. W. Johnson, Elizabeth Iannotti Buchbinder, Rizwan Haq, Frank Stephen Hodi, Jonathan Daniel Schoenfeld, Patrick Alexander Ott · 2019 · Journal for ImmunoTherapy of Cancer
79. Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy
    Evelien Schaafsma, Chloe M. Fugle, Xiaofeng Wang, Chao Cheng · 2021 · British Journal of Cancer
80. Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
    Nitin Roper, Moises J. Velez, Alberto Chiappori, Yoo Sun Kim, Jun Stephen Wei, Sivasish Sindiri, Nobuyuki Takahashi, Deborah A. Mulford, Suresh Kumar, Kris Ylaya et al. · 2021 · Nature Communications
81. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
    Conway, Jake R., Kofman, Eric, Mo, Shirley S., Elmarakeby, Haitham, Van Allen, Eliezer · 2018 · Genome Medicine
82. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
    Felicity Newell, Inês Pires da Silva, Peter A. Johansson, Alexander Maxwell Menzies, James S. Wilmott, Venkateswar Addala, Matteo Salvatore Carlino, Helen Rizos, Kátia Nones, Jarem J. Edwards et al. · 2021 · Cancer Cell
83. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
    Xin Cui, Chao Ma, Varshini Vasudevaraja, Jonathan Serrano, Jie Tong, Yansong Peng, Michael DeLorenzo, Guomiao Shen, Joshua D. Frenster, Renee‐Tyler T. Morales et al. · 2020 · eLife
84. Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
    Chung‐Han Lee, Roman Yelensky, Karin U. Jooss, Timothy An-thy Chan · 2018 · Trends in Immunology
85. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state
    Daniela Cerezo‐Wallis, Marta Contreras-Alcalde, Kevin Troulé, Xavier Catena, Cynthia Mucientes, Tonantzin G. Calvo, Estela Cañón, Cristina Tejedo, Paula Comune Pennacchi, Sabrina A. Hogan et al. · 2020 · Nature Medicine
86. Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance
    Heng Lin, Ilona Kryczek, Shasha Li, Michael D. Green, Alicia Ali, Reema Hamasha, Shuang Wei, Linda Vatan, Wojciech Szeliga, Sara Grove et al. · 2021 · Cancer Cell
87. PAK4 inhibition improves PD-1 blockade immunotherapy
    Gabriel Abril-Rodríguez, Davis Yuri Torrejon, Wei Liu, Jesse Meir Zaretsky, Theodore Scott Nowicki, Jennifer Tsoi, Cristina Puig-Saus, Ignacio Baselga-Carretero, Egmidio Medina, Michael J. Quist et al. · 2019 · Nature Cancer
88. Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
    Qingzhu Jia, Jun Wang, Ning He, Ji He, Bo Zhu · 2019 · JCI Insight
89. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer
    Kyung-Soo Kim, Seyeon Park, Sung Yong Park, Gamin Kim, Su Myeong Park, Jae-Won Cho, Dahee Kim, Young Min Park, Yoon Woo Koh, Hye Ryun Kim et al. · 2020 · Genome Medicine
90. Synthetic lethality-mediated precision oncology via the tumor transcriptome
    Joo Sang Lee, Nishanth Ulhas Nair, Gal Dinstag, Lesley M. Chapman, Youngmin Chung, Kun Wang, Sanju Sinha, Hongui Cha, Dasol Kim, Alexander V. Schperberg et al. · 2021 · Cell
91. Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation
    Mercedes Segovia, Sofía Russo, Mathías Jeldres, Yamil Damian Mahmoud, Valentina Perez, Maite Duhalde Vega, Pierre Charnet, Matthieu Rousset, Sabina Victoria, Florencia Veigas et al. · 2019 · Cancer Cell
92. Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy
    Gaopeng Li, Jae Eun Choi, Ilona Kryczek, Yilun Sun, Peng Liao, Shasha Li, Shuang Wei, Sara Grove, Linda Vatan, Reagan Nelson et al. · 2023 · Cancer Cell
93. Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
    Torrejon, Davis Y., Abril-Rodriguez, Gabriel, Champhekar, Ameya S., Tsoi, Jennifer, Campbell, Katie M., Kalbasi, Anusha, Parisi, Giulia, Zaretsky, Jesse M., Garcia-Diaz, Angel, Puig-Saus, Cristina et al. · 2020 · Cancer Discovery
94. Trial watch: Peptide-based vaccines in anticancer therapy
    Lucillia Bezu, Oliver Kepp, Giulia Cerrato, Jonathan G. Pol, Jitka Palich Fucikova, Radek Špíšek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi · 2018 · OncoImmunology
95. Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance
    Orgaz, Jose L., Crosas-Molist, Eva, Sadok, Amine, Perdrix-Rosell, Anna, Maiques, Oscar, Rodriguez-Hernandez, Irene, Monger, Jo, Mele, Silvia, Georgouli, Mirella, Bridgeman, Victoria et al. · 2020 · Cancer Cell
96. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
    Zi Yin, Min Yu, Tingting Ma, Chuanzhao Zhang, Shanzhou� Huang, Mohammad Reza Karimzadeh, Amir Abbas Momtazi‐Borojeni, Sheng Chen · 2021 · Journal for ImmunoTherapy of Cancer
97. The role of RNA methylation in tumor immunity and its potential in immunotherapy
    Yan Li, Haoer Jin, Qingling Li, Liangrong Shi, Yitao Mao, Luqing Zhao · 2024 · Molecular Cancer
98. Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
    Cheng, Jiali, Zhao, Lei, Zhang, Yuanyuan, Qin, Yun, Guan, Yuqi, Zhang, Tong, Liu, Chaohong, Zhou, Jianfeng · 2019 · Frontiers in Oncology
99. Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade
    Lee P. Richman, Robert H. Vonderheide, Andrew J. Rech · 2019 · Cell Systems
100. DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity
     Jingcheng Wu, Wenzhe Wang, Jiucheng Zhang, Binbin Zhou, Wenyi Zhao, Zhixi Su, Xun Gu, Jian Wu, Zhan Mei Zhou, Shuqing Chen · 2019 · Frontiers in Immunology